CFS CLINICAL LAUNCHES BUSINESS INTELLIGENCE PLATFORM IMPROVING DECISION-MAKING FOR CLINICAL TRIALS

CFS CLINICAL LAUNCHES BUSINESS INTELLIGENCE PLATFORM IMPROVING DECISION-MAKING FOR CLINICAL TRIALS

AUDUBON, PA –  March 7, 2013 – CFS Clinical (CFS), a specialty provider focused on the business and financial management activities for clinical trials, recently announced the launch of its upgraded technology platform and new tax  consulting services.

The enhanced InSite™ technology platform offers increased transparency for clinical trial operations, with advanced reporting capabilities offering further visibility into investigator grant payments and study startup – including grant spend forecasting and modeling, Sunshine & global transparency compliance, enterprise site profiling, and more.

"CFS Clinical is the leader in our space and has always been a pioneer in clinical business operations. By adapting our solutions to the changing needs of sponsors, CROs, and sites, CFS continues to lead the way in transforming the business of clinical trials," says Kevin Williams MBA/MS, Vice President of Corporate Development and Marketing for CFS Clinical.
In addition to the expanded business intelligence capabilities, CFS Clinical officially launched its Tax Consulting Service in January to help clients sort out the vast complexities of paying investigators globally.

"VAT rates range from 10-29%, and those rates are applied to millions of dollars of global grant payments." states April Mulroney CPA, CA, Vice President of Global Tax, Treasury and Client Services based in CFS's UK office. "CFS experts formalized this unique service to help our clients minimize financial risk and manage tax exposure on the largest line item in their clinical trial budget – the grant payments."

About CFS Clinical:
CFS Clinical is a specialty provider focused on the business and financial management activities of clinical trials.  The company offers a unique blend of contract, regulatory and cutting-edge investigator grant payment management services. With focused expertise, innovative processes, and integrated technology CFS provides high quality, cost effective service solutions that address critical study startup and financial issues affecting the clinical trials process.  CFS Clinical was founded in 2001 and is the only company in its space with a SSAE 16 SOC 1 Type II report for its investigator grant payment processing environment. For more information, visit www.cfsclinical.com.

Contact: Cindy Murray
CFS Clinical
484-690-9580
[email protected]

Suggested Articles

Boehringer Ingelheim is licensing an autotaxin inhibitor from Bridge Biotherapeutics for €45 million and promising more than €1 billion in biobucks.

In this week's EuroBiotech Report, Gilead and Galapagos ink big deal, Novartis chalks up Alzheimer’s failure and AM-Pharma raises €116 million.

In our EuroBiotech roundup this week, Oryzon posts phase 2 Alzheimer’s data, Mereo eyes fast approval and AC Immune advances Lilly-partnered drug.